Annual screening does not cut breast cancer deaths, suggests Canadian study

February 11, 2014

Annual screening in women aged 40-59 does not reduce mortality from breast cancer beyond that of physical examination or usual care, concludes a 25-year study from Canada published on bmj.com today.

Furthermore, the study shows that 22% of screen detected breast cancers were over-diagnosed, representing one over-diagnosed breast cancer for every 424 women who received screening in the trial. Over-diagnosis refers to the detection of harmless cancers that will not cause symptoms or death during a patient's lifetime.

Regular mammography screening is done to reduce mortality from breast cancer. Women with small (non-palpable) breast cancer detected by screening have better long term survival than women with palpable breast cancer. But it is not clear whether this survival difference is a consequence of organised screening or of lead time bias (when testing increases perceived survival time without affecting the course of the disease) and over-diagnosis.

So researchers based in Toronto, Canada decided to compare breast cancer incidence and mortality up to 25 years in over 89,000 women aged 40-59 who did or did not undergo mammography screening.

Women in the mammography arm of the trial had a total of five mammography screens (one a year over a five year period), while those in the control arm were not screened.

Women aged 40-49 in the mammography arm - and all women aged 50-59 in both arms - also received annual physical breast examinations. Women aged 40-49 in the control arm received a single examination followed by usual care in the community.

During the 25 year study period, 3,250 women in the mammography arm and 3,133 in the control arm were diagnosed with breast cancer and 500 and 505, respectively, died of breast cancer. "Thus, the cumulative mortality from breast cancer was similar between women in the mammography arm and in the control arm," say the authors.

At the end of the five year screening period, an excess of 142 breast cancers occurred in the mammography arm compared with the control arm, and at 15 years the excess remained at 106 cancers. This, say the authors, implies that 22% of the screen detected invasive cancers in the mammography arm were over-diagnosed - that is, one over-diagnosed breast cancer for every 424 women who received mammography screening in the trial.

They stress that these results may not be generalisable to all countries, but say, in technically advanced countries, "our results support the views of some commentators that the rationale for screening by mammography should be urgently reassessed by policy makers."

While they believe that education, early diagnosis, and excellent clinical care should continue, they conclude that annual mammography "does not result in a reduction in breast cancer specific mortality for women aged 40-59 beyond that of physical examination alone or usual care in the community."

In an accompanying editorial, Dr Mette Kalager and colleagues believe that long term follow-up does not support screening women under 60.

They agree with the study authors that "the rationale for screening by mammography be urgently reassessed by policy makers," but point out that this is not an easy task "because governments, research funders, scientists, and medical practitioners may have vested interests in continuing activities that are well established."
-end-
Research: Twenty five year follow-up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: randomised screening trial

Editorial: Too much mammography

BMJ

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.